Priority 1 from the Kidney Transplant PSP

UNCERTAINTY: In kidney transplant patients, what is the best way to manage vascular or antibody-mediated acute rejection?
Overall ranking	Priority questions agreed on but not put in ranked order
JLA question ID	0037/1
Explanatory note	Not available for this PSP
Evidence	Existing Systematic Reviews - Roberts, D M., Jiang, S H., Chadban, S J. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94(8):775-83 ~ Hychko, G., Mirhosseini, A., Parhizgar, A., Ghahramani, N. A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection. International Journal of Organ Transplantation Medicine. 2011;2(2):51-6 Ongoing Randomised Controlled Trial - Eskandary, F., Bond, G., Schwaiger, E., Kikic, Z., Winzer, C., Wahrmann, M., Marinova, L., Haslacher, H., Regele, H., Oberbauer, R., et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15(1):107
Health Research Classification System category	Renal and Urogenital

Extra information provided by this PSP
Original uncertainty examples	How to treat acute and chronic antibody mediated rejection? What is the role of eculizumab in vascular rejection with an antibody mediated component? How should acute antibody-mediated rejection be treated? What is the best strategy for managing antibody mediated rejection?
Comparison	Drug
Submitted by	Clinicians x 4
Outcomes to be measured	Patient and graft survival, graft function, adverse events

PSP information
PSP unique ID	0037
PSP name	Kidney Transplant
Total number of uncertainties identified by this PSP.	90 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop	3 February 2016